CAPR$6.938.62%0.55
Capricor Therapeutics Inc (CAPR)
Date: 2026-11-02 16:00O: 6.80H: 7.46L: 6.67C: 6.93Vol: 2.319M
Capricor Therapeutics Inc stock is traded at $6.93, with a volume of 2,708,218. It is up +8.62% in the last 24 hours and down -22.57% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Previous Close:
$6.38
Open:
$6.80
24h Volume:
2,708,218
Relative Volume:
1.03
Market Cap:
$402.90M
Revenue:
$11.13M
Net Income/Loss:
-$114.59M
P/E Ratio:
-
EPS:
-$2.31
Net Cash Flow:
-$113.96M
1W Performance:
+20.73%
1M Performance:
-22.57%
6M Performance:
-77.58%
1Y Performance:
+6.45%
1-Day Range:
$6.67$7.46
1-Week Range:
$5.67$6.93
52-Week Range:
$2.96$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(310) 358-3200Address
10865 ROAD TO THE CURE, SAN DIEGO, CA, USACompare CAPR vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
CAPR Capricor Therapeutics Inc | $402.90M | $22.27M | -$129.42M | -$113.96M | -$2.31 |
 VRTX Vertex Pharmaceuticals Inc | $142.98B | $12.59B | $4.41B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $100.44B | $16.90B | $4.82B | $3.79B | $41.04 |
 MRNA Moderna Inc | $90.08B | $2.23B | -$3.15B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $55.64B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $41.05B | $6.13B | $655.71M | $1.10B | $4.48 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
- Krasney KarenJun 25 '26EVP, GENERAL COUNSEL
- Transaction
- Sale
- Cost
- $30.38
- #Shares
- 24,100
- Value ($)
- 732,158
- #Shares Total
- 30,547
- Bergmann AnthonyJun 25 '26CHIEF FINANCIAL OFFICER
- Transaction
- Sale
- Cost
- $30.38
- #Shares
- 24,100
- Value ($)
- 732,158
- #Shares Total
- 11,223
- Bergmann AnthonyJun 25 '26CHIEF FINANCIAL OFFICER
- Transaction
- Option Exercise
- Cost
- $3.18
- #Shares
- 24,100
- Value ($)
- 76,638
- #Shares Total
- 35,323
- Krasney KarenJun 24 '26EVP, GENERAL COUNSEL
- Transaction
- Sale
- Cost
- $30.00
- #Shares
- 400
- Value ($)
- 12,000
- #Shares Total
- 30,547
- Bergmann AnthonyJun 24 '26CHIEF FINANCIAL OFFICER
- Transaction
- Sale
- Cost
- $30.00
- #Shares
- 400
- Value ($)
- 12,000
- #Shares Total
- 11,223
- Bergmann AnthonyJun 24 '26CHIEF FINANCIAL OFFICER
- Transaction
- Option Exercise
- Cost
- $3.18
- #Shares
- 400
- Value ($)
- 1,272
- #Shares Total
- 11,623
- Krasney KarenJun 24 '26EVP, GENERAL COUNSEL
- Transaction
- Option Exercise
- Cost
- $3.18
- #Shares
- 400
- Value ($)
- 1,272
- #Shares Total
- 30,947
- Bergmann AnthonyJun 22 '26CHIEF FINANCIAL OFFICER
- Transaction
- Option Exercise
- Cost
- $3.18
- #Shares
- 500
- Value ($)
- 1,590
- #Shares Total
- 11,723
- Krasney KarenJun 22 '26EVP, GENERAL COUNSEL
- Transaction
- Option Exercise
- Cost
- $3.18
- #Shares
- 500
- Value ($)
- 1,590
- #Shares Total
- 31,047
- Krasney KarenJun 22 '26EVP, GENERAL COUNSEL
- Transaction
- Sale
- Cost
- $30.00
- #Shares
- 500
- Value ($)
- 15,000
- #Shares Total
- 30,547
